Coming Soon

Testing BI 765179 alone and in combination with ezabenlimab in advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in advanced head and neck cancer

This study is being done to see if the study drug, called BI 765179, in combination with another drug called pembrolizumab, can help people with advanced head and neck cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Sumita Trivedi
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Head and Neck)

IRB Number

24-2837

ClinicalTrials.gov

NCT04958239

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.